Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: APC for Endometriosis
The study is a prospective, monocentric, randomly assigned controlled, two-armed, pilot-study conducted at Department for Women's Health, Tuebingen, Germany. In this Post Market Study it will be determined whether and to what extent the two surgical procedures for ovarian endometrioma treatment (standard cystectomy versus APC) may affect the ovarian reserve by comparing changes in serum AMH levels after treatment.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are APC, or Lap bipolar forceps. The registry lists allocation as randomized. The study is a prospective, monocentric, randomly assigned controlled, two-armed, pilot-study conducted at Department for Women's Health, Tuebingen, Germany.
They plan to enroll about 72 people at Tübingen. Taking part typically means using or being fitted with a device plus check-ins.
Official title (unrewritten)
Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy: A Prospective Controlled Randomized Pilot Study
Interventions: APC, Lap bipolar forceps
Primary outcome (registry wording): Concentration of AMH (Anti-Müller hormone) level
Who it is for (from inclusion criteria)
Ages 18 Years to 40 Years
Women only
Indication for surgical endometrioma treatment according to patient symptoms
Who the registry excludes
Expected lack of patient compliance or inability of the patient to understand the purpose of the clinical trial
Prior procedures at the ovaries
Recurrent endometrioma (patients with recurrent endometriosis outside of the ovar, e.g. peritoneal endometriosis lesions can be included)
Pregnant or breastfeeding patients
Participation in any other clinical study that could affect the AMH level or pregnancy
This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors.
The goal of this watch-and-measure (no experimental treatment required) study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test
Endometriosis, a chronic gynecological disorder associated with pain and infertility, is a common condition affecting approximately one in ten women. Up to 50% of patients with endometriosis have ovarian endometriomas (or "chocolate cysts").
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07065214?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07065214?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.